Yatiri Bio Enters Exclusive Licensing Option for AML Treatment
Yatiri Bio, a precision medicine company, announced on March 24, 2026, that it has entered into an exclusive global option to license agreement with Oscotec for denfivontinib, a multikinase inhibitor targeted at Acute Myeloid Leukemia (AML), according to GlobeNewswire PE. Under the agreement, Yatiri Bio holds the exclusive option to license denfivontinib for its development and commercialization.
Agreement Details
Yatiri Bio’s ProteoCharts™ platform uses deep neural networks to integrate proteomic profiling with clinical data and functional testing in patient-derived models, enabling the identification of a novel biomarker profile for AML patients responsive to denfivontinib. This biomarker profile is FLT3-independent, allowing denfivontinib to target a broader AML patient population compared to traditional FLT3 inhibitors. Yatiri Bio is developing a Laboratory Determined Test (LDT) at its CLIA/CAP-accredited facility to stratify patients for denfivontinib clinical trials, which helps ensure enrollment of responsive populations and accelerates the path to regulatory approval.
Yatiri Bio’s Technology and Strategy
The company’s ProteoCharts™ platform creates predictive stratification models for diseases like AML by combining unbiased proteomic profiling with clinical and functional data. Yatiri Bio has identified that denfivontinib addresses an unmet clinical need by targeting patients underserved by current standards of care, positioning it as a first-in-class solution. This approach allows Yatiri Bio to differentiate denfivontinib from other therapies through its unique biomarker-driven strategy, according to GlobeNewswire PE.
Company Perspectives
Pilgrim Jackson, CEO of Yatiri Bio, stated, ‘This agreement exemplifies our strategy of using AI-driven proteomic intelligence to unlock hidden clinical value in oncology assets.’ Oscotec CEO Taeyoung Yoon added, ‘This collaboration with Yatiri Bio demonstrates Oscotec’s commitment to the global trend in drug development: AI-based precision medicine.’ This agreement represents a model for AI-enabled asset optimization by combining the therapeutic candidate with existing human data and Yatiri Bio’s proteomic AI platform.
